Printer Friendly

DNX PRODUCES TRANSGENIC SWINE THAT EXPRESS 25 PERCENT HUMAN HEMOGLOBIN; COMPANY INCREASES EXPRESSION LEVEL 150 PERCENT TO RECORD HIGH

 PRINCETON, N.J., Sept. 7 /PRNewswire/ -- DNX Corporation (NASDAQ: DNXX) today announced that it has successfully developed and bred genetically engineered swine that express approximately 25 percent authentic human hemoglobin. This represents a 150 percent increase over previously achieved levels.
 "One of our goals for 1993 was to produce new lines of transgenic pigs expressing greater than 20 percent human hemoglobin to total swine hemoglobin," said Paul J. Schmitt, president and CEO. "It is gratifying to have attained this important milestone. This level of expression, 32 grams/per liter of blood, establishes the feasibility of using genetically engineered swine to produce large volumes of human pharmaceutical proteins, such as hemoglobin, in a cost effective manner."
 DNX developed its first transgenic pigs that produced human hemoglobin in June 1991. In January 1992, DNX successfully developed swine that expressed clinically relevant levels of human hemoglobin, approximately 10 percent human-to-swine. The newly developed animals, including a second generation progeny produced through natural breeding, are the first to possess a commercially relevant level of human hemoglobin expression.
 Hemoglobin, the primary constituent of red blood cells, transports oxygen from the lungs to the body's tissues and organs. Recombinant human hemoglobin produced in transgenic swine, however (cell-free hemoglobin), must be modified with cross-linking technologies to create blood substitutes that may be safe and efficacious. During 1992 and 1993, DNX acquired several promising cross-linking technologies. The blood substitute under development at DNX would:
 -- be free from contamination with human blood borne viruses, such as HIV and hepatitis,
 -- be universally compatible (i.e., would have no need to type and cross-match recipients and donors), and
 -- potentially have significantly better storage characteristics than human red blood cells.
 "While we have made significant progress and attained key milestones in the blood substitutes program, we are still in the process of evaluating corporate partners for this area of research," said Mr. Schmitt. "Our capital resources would allow us to maintain the high-level expenditures necessary for continuing research in this area for approximately 12 months. Should partnering efforts not be successful in the near future, we will reassess our efforts in this area and our ability to sustain a program which requires such a large capital expenditure."
 DNX is a leader in the research and development of therapeutic products and biological testing services based on transgenic animal technology. Biological testing services employing Biodigm(R) animal models will be marketed through DNX's wholly owned subsidiary, Pharmakon Research International, Inc.
 -0- 9/7/93
 /CONTACT: Paul J. Schmitt, president and CEO of DNX Corporation, 609-520-0300, or Kathryn Comba or Rhonda Chiger of Noonan/Russo Communications, 212-696-4455/
 (DNXX)


CO: DNX Corporation ST: New Jersey IN: MTC SU:

LG-TS -- NY014 -- 9180 09/07/93 08:37 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 7, 1993
Words:451
Previous Article:ON THE BORDER CAFES, INC. ANNOUNCES OPENING OF FRANCHISED RESTAURANT IN NASHVILLE
Next Article:ELECTROCHEMICAL INDUSTRIES (FRUTAROM) LTD. REPORTS ON EXERCISE OF THE COMPANY'S WARRANTS -- SERIES A
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters